This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Liver Fluke Treatment Market

Liver Fluke Treatment Market by Drug Type, Route of Administration, Application, Distribution Channel & Region - Forecast 2022 - 2032

Market Insights on Liver Fluke Treatment covering sales outlook, demand forecast & up-to-date key trends

Liver Fluke Treatment Market

The global liver fluke treatment market is estimated to register growth at a healthy CAGR of around 4% to 5% during the forecast period 2022-2032. Increasing research and development activities aimed at developing more effective therapeutic drugs for the treatment of liver-related diseases are projected to create growth prospects in the liver fluke treatment market over the forthcoming years.

Report Attribute

Details

Liver Fluke Treatment Market Projected Growth Rate (2022-2032)

4% to 5% CAGR

Liver fluke is a collective name of a polyphyletic parasitic trematodes group that infect humans as well as animals and cause ailment related to the liver and bile duct. These parasitic worms are commonly categorized into 2 types of infection-causing worms and termed as Fasciola Gigantica and Fasciola Hepatica, which is also known as sheep liver fluke.

Fascioliasis is an infectious disease caused by these parasites that results in severe abdominal pain, fever, hives, malaise, diarrhea, and others. Many times liver fluke infections go undiagnosed or misdiagnosed with general abdominal pain. However, growing awareness regarding the severity of the disease and the introduction of novel treatments is favoring the growth in the market.

Which are Key Drivers Augmenting the Sales of Liver Fluke Treatment in the Global Market

Over the last decade, the prevalence of infectious diseases such as liver fluke is growing at a rapid pace. This is due to the declining global immunity and rising consumption of salads comprising water-based leaves such as watercress, resulting in fueling the demand for associated diagnostics and treatment solutions.

For instance, according to the survey by the American Journal of Tropical Medicine and Hygiene, nearly 2.6 million people are estimated to be affected by fascioliasis and around 91 million people are at the risk of developing the infection across the world. As liver fluke therapeutics drugs such as praziquantel, triclabendazole, bithionol, albendazole, and nitazoxanide among others play a vital rise in the treatment of fascioliasis, rising burden of these infectious diseases is expected to drive the sales in the global market.

Customize this Report

Let us know your requirement to get
100% FREE customization

What are the Factors Creating Restraints for the Growth in the Global Liver Fluke Treatment Market

There are numerous side effects related to the consumption of liver fluke treatment drugs such as praziquantel, albendazole, and nitazoxanide including itching, fever, dizziness, hair loss, vomiting, discolored urination, and others. Growing awareness regarding these side effects in hindering the sales in the market.

Also, stringent approval policies and regulations regarding the launch of novel liver fluke treatment solutions across various countries are further restraining the growth in the market.

Why is East Asia Garnering Maximum Sales of Liver Fluke Treatment in the Market

Future Market Insights reveals that East Asia is estimated to account for a lion’s share in the global liver fluke treatment market from 2022 to 2032.

With increasing emphasis on increasing the export of meat, wool, livestock, and others, the government of several countries are focusing on undertaking several initiatives to increase the breeding and population of cattle such as sheep.

For instance, as per the Food and Agriculture Organization, the population of sleep was reported to reach 16.58 Mn by 2019, exhibiting a year-on-year growth of around 1.2%. As sheep are highly prone to liver flukes, growing sheep population is projected to create lucrative opportunities in the East Asia market.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

How is North America Contributing to the Growth in the Liver Fluke Treatment Market

As per a study by FMI, North America is anticipated to emerge as a highly remunerative market for liver fluke treatment during the forecast period 2022-2032.

A number of players in the market are focusing on developing and launching novel therapeutic drugs with minimal side effects and aiming at receiving product approval to cater to the surging demand for effective liver fluke treatment solutions in North America.

For instance, in 2019, Novartis, a global healthcare company, announced receiving Food & Drug Administration approval for its new liver fluke treatment drug, Egaten (triclabendazole), for patients six years of age and older in the U.S. A multiplicity of such developments is expected to drive the growth in the North America market.

Market Competition

Some of the leading players in the liver fluke treatment market are Novartis, GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc, Bayer HealthCare Pharmaceuticals Inc., Par Pharmaceutical, Romark Laboratories, L.C., Lupin Pharma, Schering Corporation among others.

Attributed to the presence of such high number of participants and increasing research and development activities for novel liver fluke treatment drug, the market is highly competitive.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Scope of Report

Report Attribute

Details

Growth Rate       

CAGR of 4% to 5% from 2022 to 2032

Base Year for Estimation

2021

Historical Data

2015-2020

Forecast Period

2022-2032

Quantitative Units

Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Drug Type
  • Route of Administration
  • Application
  • Distribution Channel
  • Region

Countries Covered

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa

Key Companies Profiled

  • Novartis
  • GlaxoSmithKline Plc.
  • Merck & Co., Inc.
  • Pfizer Inc
  • Bayer HealthCare Pharmaceuticals Inc.
  • Par Pharmaceutical
  • Romark Laboratories, L.C.
  • Lupin Pharma
  • Schering Corporation
  • Others

Customization

Available Upon Request

Key Segments Profiled in the Liver Fluke Treatment Market Survey

By Drug Type:

  • Triclabendazole
  • Praziquantel
  • Bithionol
  • Nitazoxanide
  • Albendazole

By Route of Administration:

  • Oral
  • Intravenous
  • Intramuscular
  • Topical

By Application:

  • Human
  • Cattle
  • Sheep
  • Others

By Distribution Channel:

  • Government Healthcare Centers
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacy

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa

Frequently Asked Questions

FMI projects the sales of liver fluke treatment in the market is expected to rise at 4% to 5% value CAGR by 2032

The global liver fluke treatment market is expected to be dominated by East Asia over the forecast period 2022-2032.

Novartis, GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc, Bayer HealthCare Pharmaceuticals Inc., Par Pharmaceutical, Romark Laboratories, L.C., Lupin Pharma, Schering Corporation, and others are some of the leading players in the key liver fluke treatment market.

Table of Content

NA

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

NA

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts

NA

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Hirschsprung Disease Treatment Market

Published : September 2017

Healthcare

Winter Sports Injury Treatment Market

Published : January 2016

Healthcare

Kids Sports Injury Treatment Market

Published : January 2016

Healthcare

Leukemia Therapeutics Treatment Market

Published : February 2022

Google translate

Liver Fluke Treatment Market